Healthcare Industry News: Betaseron
News Release - January 5, 2007
Diamics Appoints Christine A. Meda as PresidentNOVATO, Calif.--(HSMN NewsFeed)--Diamics, Inc., a San Francisco Bay-area medical device and diagnostics company, announced today it has appointed Christine A. Meda as President.
"We are pleased to have Christine Meda join our team at this exciting time for our company," said Peter Gombrich, CEO, Diamics, Inc. "Her in-depth industry experience and insight--particularly concerning women's health issues--will help us to accelerate the development of our molecular-based cancer screening and diagnostic systems."
Meda takes over the position from Gombrich, who has been serving in dual capacities as both President and CEO. He will continue as the company's CEO and Chairman of the Board.
Meda comes to Diamics, Inc. from Roche Molecular Systems, a division of Hoffman-LaRoche, where she served as VP of Business Development and VP of the Women's Health portfolio. In this latter capacity, she directed the launches of real-time PCR diagnostic products for Chlamydia, Human Papillomavirus (HPV), Herpes Simplex virus and Strep B.
Previously Meda served as Senior Director of the CNS portfolio at Schering AG pharmaceuticals, where she oversaw life cycle and marketing activities for Betaseron, a multiple sclerosis treatment, and as Medical Affairs Director, responsible for clinical trials for their hematological oncology drugs: Fludara, CamPath and Leukine.
She also held executive positions at Bio-Rad Laboratories, Meridian Diagnostics, and Diagnostic Products Corporation.
Meda earned a B.S. degree from State University of New York, Potsdam Campus, and has completed numerous executive development programs at Diagnostic Products, Schering AG and Roche.
About Diamics, Inc.
Diamics, Inc. is a privately owned medical device and diagnostics company located in Novato, California. The company is committed to developing, manufacturing, and marketing cost-effective, molecular-based cancer screening and diagnostic systems that will increase long-term survival rates through early detection. Diamics has a mature management team with an extensive track record in the medical device and diagnostics industries. The company's goals are to help medical personnel worldwide improve lives and to create value for investors, employees and all who use and benefit from its proprietary technology. Please visit www.diamics.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.